REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
—————————
For the month of September 2005

Form 20-F x

Form 40-F o

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): _____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): _____

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes o

No x

If “Yes” marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-________

 

---

On September 6 and 9, 2005, sanofi-aventis issued the press releases attached hereto as Exhibits 99.1 and 99.2, which are incorporated herein by reference.

 

Exhibit List

 

Exhibit No.	Description
Exhibit 99.1	Press Release dated September 6, 2005, concerning program evaluating clopidogrel
Exhibit 99.2	Press Release dated September 9, 2005, concerning FDA advisory committee recommendation with respect to Exubera®

2

---

           Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: September 9, 2005	SANOFI-AVENTIS
By:	/s/ Patricia Kodyra
	Name: Patricia Kodyra Title:  Associate Vice President            Financial and Securities Law

 

 

3

---

 

Exhibit List

 

Exhibit No.	Description
Exhibit 99.1	Press Release dated September 6, 2005, concerning program evaluating clopidogrel
Exhibit 99.2	Press Release dated September 9, 2005, concerning FDA advisory committee recommendation with respect to Exubera®

 

4

---